Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study

• Principais autores: Mónica López-Lacort (Autor), Ana Corberán-Vallet (Autor), Francisco J. Santonja (Autor), Cintia Muñoz-Quiles (Autor), Javier Díez-Domingo (Autor), Alejandro Orrico-Sánchez (Autor)
• Formato: Livro
• Publicado em: Elsevier, 2024-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...